Mesenchymal Stem or Stromal Cells from Amnion and Umbilical Cord Tissue and Their Potential for Clinical Applications

Lindenmair, Andrea; Hatlapatka, Tim; Kollwig, Gregor; Hennerbichler, Simone; Gabriel, Christian; Wolbank, Susanne; Redl, Heinz; Kasper, Cornelia

doi:10.3390/cells1041061

Cited by 98 publications

(85 citation statements)

References 139 publications

(376 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…8 Human umbilical cord mesenchymal stem cells also capable to differentiate into fibrocartilage lineage, forming type I and type II collagen, and aggrecan synthesis.…”

Section: 4mentioning

confidence: 99%

Chondrogenic Differentiation Capacity of Human Umbilical Cord Mesenchymal Stem Cells with Platelet Rich Fibrin Scaffold in Cartilage Regeneration (In Vitro Study)

Sumarta

Hendrianto

et al. 2016

Bali Med J.

View full text Add to dashboard Cite

Background: Human umbilical cord mesenchymal stem cell is a promising source of allogenous MSC with great chondrogenic differentiation capacity. Meanwhile, platelet rich fibrin (PRF) is a natural fibrin matrix, rich in growth factors, forming a smooth and flexible fibrin network, supporting cytokines and cell migration, thus can be used as a scaffold that facilitate the differentiation of MSC. However, the differential capability of MSC cultured in PRF was still poorly understood. Method:We studied in vitro differentiation potential of MSC cultured in PRF by evaluating several markers such as FGF 18, Sox 9, type II collagen, aggrecan in 3 different culture medium. Result: The result showed that there was positive expression of FGF 18, Sox 9, type II collagen, aggrecan in all medium of in vitro culture. Conclusion: MSC cultured from human umbilical cord had the capacity of chondrogenic differentiation and able to produce cartilage extracellular matrix in vitro which means that hUCMSC is a potential allogeneic MSC for cartilage regeneration.

show abstract

“…8 Human umbilical cord mesenchymal stem cells also capable to differentiate into fibrocartilage lineage, forming type I and type II collagen, and aggrecan synthesis.…”

Section: 4mentioning

confidence: 99%

Chondrogenic Differentiation Capacity of Human Umbilical Cord Mesenchymal Stem Cells with Platelet Rich Fibrin Scaffold in Cartilage Regeneration (In Vitro Study)

Sumarta

Hendrianto

et al. 2016

Bali Med J.

View full text Add to dashboard Cite

show abstract

“…MSCs are plastic-adherent-multipotent stem cells that are able to differentiate to at least osteo, adipo, and chondrocytes and also several other cell types (Dominici et al 2006;Li et al 2013b). They are easily isolated from bone marrow, adipose tissue, peripheral blood, dermis, umbilical cord (UC), umbilical cord blood (UCB), amnion fluid, and placenta, somehow without any invasive procedure (Choudhery et al 2013;Koliakos et al 2011;Lee et al 2010;Lindenmair et al 2012;Mennan et al 2013;Ribeiro et al 2013). Despite some differences between MSCs originated from various sources, they share the main characteristics mentioned above (Al-Nbaheen et al 2013;Choudhery et al 2013;Jin et al 2013).…”

Section: Introductionmentioning

confidence: 99%

In vitro augmentation of mesenchymal stem cells viability in stressful microenvironments

Amiri

Jahanian-Najafabadi

Roudkenar

2015

Cell Stress and Chaperones

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs) are under intensive investigation for use in cell-based therapies because their differentiation abilities, immunomodulatory effects, and homing properties offer potential for significantly augmenting regenerative capacity of many tissues. Nevertheless, major impediments to their therapeutic application, such as low proliferation and survival rates remain as obstacles to broad clinical use of MSCs. Another major challenge to evolution of MSC-based therapies is functional degradation of these cells as a result of their exposure to oxidative stressors during isolation. Indeed, oxidative stress-mediated MSC depletion occurs due to inflammatory processes associated with chemotherapy, radiotherapy, and expression of pro-apoptotic factors, and the microenvironment of damaged tissue in patients receiving MSC therapy is typically therapeutic not favorable to their survival. For this reason, any strategies that enhance the viability and proliferative capacity of MSCs associated with their therapeutic use are of great value. Here, recent strategies used by various researchers to improve MSC allograft function are reviewed, with particular focus on in vitro conditioning of MSCs in preparation for clinical application. Preconditioning, genetic manipulation, and optimization of MSC culture conditions are some examples of the methodologies described in the present article, along with novel strategies such as treatment of MSCs with secretome and MSC-derived microvesicles. This topic material is likely to find value as a guide for both research and clinical use of MSC allografts and for improvement of the value that use of these cells brings to health care.

show abstract

“…Thus, AM exhibits tremendous potential for therapeutic purposes due to its absorption, high biocompatibility, regenerative capacity and ease of implementation. It is easily accessible and is without ethical concerns [14].…”

Section: Amniotic Membranementioning

confidence: 99%

Amniotic membrane as a potent source of stem cells and a matrix for engineering heart tissue

Francisco¹,

Cunha²,

Simeoni³

et al. 2013

JBiSE

View full text Add to dashboard Cite

Existing therapies for the treatment of chronic heart failure still have some limitations and there is a pressing need for the development of new therapeutic modalities. The amniotic membrane has been used for the treatment of various diseases, such as conjunctive defects; however, the mechanisms behind its repair functions are still unclear. Regenerative medicine is seeking newer alternatives and among them, biomaterials have emerged in recent years for developing and manipulating molecules, cells, tissues or organs grown in laboratories in order to replace human body parts. Many such materials have been used for this purpose, either synthetically or biologically, in order to provide new medical devices. This review provides a wider view of the regeneration potential of the use of amniotic membrane as a potential biomaterial to facilitate the implementation of new research in surgical procedures. Amniotic membrane appears to be an alternative source of stem cells as well as an excellent biomaterial for cell-based therapeutic applications in engineering heart tissue.

show abstract

Mesenchymal Stem or Stromal Cells from Amnion and Umbilical Cord Tissue and Their Potential for Clinical Applications

Cited by 98 publications

References 139 publications

Chondrogenic Differentiation Capacity of Human Umbilical Cord Mesenchymal Stem Cells with Platelet Rich Fibrin Scaffold in Cartilage Regeneration (In Vitro Study)

Chondrogenic Differentiation Capacity of Human Umbilical Cord Mesenchymal Stem Cells with Platelet Rich Fibrin Scaffold in Cartilage Regeneration (In Vitro Study)

In vitro augmentation of mesenchymal stem cells viability in stressful microenvironments

Amniotic membrane as a potent source of stem cells and a matrix for engineering heart tissue

Contact Info

Product

Resources

About